OUR HAEMATOLOGY TRIALS
Advancing care for blood cancers and blood disorders
MULTIPLE MYELOMA
Bispecific T-cell Engager (BiTE)
BiTE molecule targeting BCMA / CD3
EMB06X101
A First-in-Human, Phase I/II, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumour Activity of
EMB-06 in Patients with Recurrent or Refractory Multiple Myeloma
PHASE
I/II
STATUS
Recruiting
Bispecific Antibody
Bispecific antibody targeting CD38 / CD47
ISB 1442-101
A Phase 1/2, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose-Expansion Study of Single-Agent ISB 1442 in Patients with Relapsed/Refractory Multiple Myeloma
PHASE
I/II
STATUS
Recruiting
Bispecific Antibody
BCMA/CD3 BiTE vs SOC
R5458-ONC-2245 (LINKER-MM3)
An Open-label, Randomized, Phase 3 Study of Linvoseltamab Versus the Combination of Elotuzumab, Pomalidomide, and Dexamethasone (EPd), in Patients With Relapsed/Refractory Multiple Myeloma (LINKER-MM3)
PHASE
III
STATUS
Coming Soon
MYELOID LEUKEMIA / MYELODYSPLASIA
Cell Death (Apoptosis) Promoter
Bcl-2 inhibitor
BGB-11417-103
A Phase Ib/II, Open-Label, Dose-Finding, and Expansion Study of the Bcl-2 Inhibitor BGB-11417 in Patients with Myeloid Malignancies
PHASE
Ib/II
STATUS
Recruiting
Myeloid Kinase Inhibitor
FLT-3, SYK, JAK, c-KIT inhibitor +/- venetoclax
HM-FLTI-101 (APTIVATE)
A Phase 1/2 Open Label, Multicenter, Dose Escalation and Expansion Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM43239 (Tuspetinib) in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
PHASE
I/II
STATUS
Coming Soon
LYMPHOID MALIGNANCIES (NHL/CLL/HL)
Immunotherapy Combination
anti-CD20 + anti-CD37
PSB202-01
A Phase Ia/Ib Study of PSB202 in Patients with Previously Treated, Relapsed, Indolent B-Cell Malignancies
PHASE
Ia/b
STATUS
Recruiting
Bispecific T-cell Engager (BiTE)
BiTE molecule targeting CD20 / CD3
GB261-001
A Phase I/II, Open-Label, Multicentre Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of GB261 in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
PHASE
I/II
STATUS
Recruiting
Bruton’s Tyrosine Kinase (BTK) Inhibitor
Non-covalent BTKi vs covalent BTKi
LOXO-BTK-20030 (BRUIN-CLL-314)
A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) versus Ibrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
PHASE
III
STATUS
Recruiting
Immunoconjugate
anti-CD19 / Glucocorticoid Receptor Modulator conjugate
M22-716
A First In Human Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-319 in B-cell Malignancies
PHASE
I
STATUS
Recruiting
MYELOFIBROSIS AND MYELOPROLIFERATIVE DISORDERS
Fibrosis attenuator
Lysyl oxidase inhibitor
PXS5505-MF-101
A Phase I/IIa Study to Evaluate Safety, Pharmacokinetic, and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients with Primary, Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis
PHASE
I/IIa
STATUS
Recruiting
Targeted Therapy Combination
JAK2 inhibitor plus BET inhibitor
CPI 0610-04 (MANIFEST-2)
A Phase III, Randomised, Double-Blind, Active-Controlled Study of Pelabresib (CPI 0610) and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naiive MF Patients
PHASE
III
STATUS
Closed to Recruitment
Targeted Therapy
Hepcidin mimetic
PTG-300-11 (PERSIST)
A Phase III Study of the Hepcidin Mimetic Rusfertide (PTG-300) in Patients with Polycythemia Vera
PHASE
III
STATUS
Recruiting
Targeted Therapy Combination
BETi +/- JAK2i
CA011-023
A Phase 1b/2 Study of BMS-986158 Monotherapy and in Combination with Either Ruxolitinib or Fedratinib in Participants with DIPSS-Intermediate or High Risk Myelofibrosis